An emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans - AspenBio Pharma, Inc. (OTC Bulletin Board: APNB) – has recently filed an Investigational New Animal Drug Application (INADA) to the USFDA’s Center for Veterinary Medicine.
The said INADA application officially commences the FDA approval process for StayBred™, AspenBio Pharma’s largest revenue potential single-chain drug, with a U.S. market potential estimated to exceed $200 million annually.
StayBred™ is AspenBio Pharma’s innovative new product that contains a recombinant single-chain LH analog designed to help dairy cows maintain pregnancy, thus increasing milk production and reducing overall reproduction costs.
According to Richard Donnelly, president and CEO of AspenBio Pharma:
Find more details from the press release."This INADA filing for StayBred represents an important milestone for the company. This new drug has the potential to deliver substantial economic benefit to dairy producers, including increasing milk production and reducing reproduction costs.
This milestone also reveals the major progress we have achieved in advancing our product pipeline, and it strengthens confidence in our development strategy and long-term potential.
We remain highly focused on advancing all of our products and are already exploring various marketing and distribution opportunities, including discussions with prospective licensing partners."
Comment Preview